Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Program leadership team: Jose Pablo Leone, MD; Wenya Linda Bi, MD, PhD; Eudocia Q. Lee, MD, MPH; Nancy Lin, MD; and Ayal Aizer, MD, MHS
When breast cancer spreads, it can travel to distant sites in the body such as the liver, bone, lungs, or brain. The treatment of patients with breast cancer that has spread to the brain (called brain metastases) or spinal fluid (called leptomeningeal
disease) requires a dedicated team of experts across several specialties.
At the Program for Patients with Breast Cancer Brain Metastases at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) you will receive care from a coordinated, multidisciplinary team of internationally recognized experts including medical oncologists,
radiation oncologists, neurosurgeons, neuro-oncologists, neuroradiologists, and pathologists, who work together to provide the highest-level care.
There is no "one size fits all" approach for metastatic breast cancer, especially for patients whose cancer has spread to the brain. We will assess which team of specialists makes the most sense for you to see, given your specific situation, and create a personalized treatment plan for you. We will coordinate your care so that all feasible approaches to treatment are considered, and you receive the treatment that is best for you.
More information about our approach to treating brain metastases
Information about scheduling an appointment or referring a patient to our program
New Patient Appointments
Program for Patients with Breast Cancer Brain MetastasesNancy Lin, MD, discusses Dana-Farber's approach to treating patients with breast cancer brain metastases.